Table 1 Baseline characteristics of the studies included
Study | Cancer type | Interventions | Follow-up (mon) | N (denosumab/ZA) | Primary endpoint |
|---|---|---|---|---|---|
Stopeck et al. (2010) [22] | Breast cancer | Denosumab 120 mg SC versus ZA 4 mg IV | 33 | 1026/1020 | Time to first SRE |
Fizazi et al. (2011) [21] | Prostate cancer | Denosumab 120 mg SC versus ZA 4 mg IV | 40.5 | 943/945 | Time to first SRE |
Henry et al. (2014) [23] | Various solid tumors | Denosumab 120 mg SC versus ZA 4 mg IV | 34 | 800/797 | Time to first SRE |
Raje et al. (2018) [20] | Multiple myeloma | Denosumab 120 mg SC versus ZA 4 mg IV | 50 | 859/859 | Time to first SRE |